Spero Therapeutics, Inc. (SPRO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Spero Therapeutics reported revenue of $66.8M, up 39.2% from $48.0M the year before. Net income was $8.6M (a 12.8% net margin), or $0.15 per diluted share. Operating margin was 9.5%. Operating activities generated -$12.6M of cash. At fiscal year end, Spero Therapeutics held $68.9M in total assets against $9.9M in total liabilities, including $40.3M of cash and equivalents.
Open the full interactive Spero Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Spero Therapeutics Key Stats
| Share Price | $1.15 |
|---|---|
| Market Cap | $66.7M |
| P/E Ratio | 7.7 |
| Revenue YoY Growth | +39.2% |
| 52-Week Range | $1.11 – $2.98 |
| Shares Outstanding | 58.0 million (basic, 2026 Q2) |
Spero Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | $18.3M | $53.5M | $103.8M | $48.0M | $66.8M |
| Operating Income | -$79.1M | -$88.0M | -$42.2M | $21.5M | -$73.4M | $6.3M |
| Pre-Tax Income | -$78.3M | -$89.8M | -$46.4M | $25.4M | -$68.6M | $8.8M |
| Income Tax | $0 | $0 | $0 | $2.6M | $0 | $261,000 |
| Net Income | -$78.3M | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.6M |
| Diluted EPS | -$3.52 | -$2.91 | -$1.23 | $0.43 | -$1.27 | $0.15 |
Spero Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $5.4M | $41.3M | $258,000 | $0 |
| Net Income | -$7.4M | $31.5M | -$7.2M | -$9.6M |
| Diluted EPS | -$0.13 | $0.53 | -$0.13 | -$0.16 |
Spero Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.2M | $112.6M | $109.1M | $76.3M | $52.9M | $40.3M |
| Current Assets | $139.1M | $157.9M | $113.6M | $131.2M | $107.3M | $67.3M |
| Total Assets | $153.5M | $171.1M | $124.8M | $182.4M | $110.5M | $68.9M |
| Current Liabilities | $14.3M | $18.7M | $21.6M | $37.2M | $49.1M | $8.9M |
| Total Long-Term Debt | $177,000 | $138,000 | $96,000 | $87,000 | — | $91,000 |
| Total Liabilities | $21.4M | $82.8M | $48.9M | $75.5M | $64.4M | $9.9M |
| Shareholders' Equity | $132.0M | $88.3M | $75.9M | $106.9M | $46.1M | $59.0M |
Spero Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$85.9M | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Cash From Investing | $10.5M | $7.7M | $33.8M | $0 | — | — |
| Cash From Financing | $130.9M | $84.0M | -$29.6M | $221,000 | $0 | — |
| Free Cash Flow | -$86.0M | — | — | — | — | — |
Figures from Spero Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Spero Therapeutics financials page for every line item.
Spero Therapeutics Company Profile
| Ticker | SPRO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001701108 |
Frequently Asked Questions
What was Spero Therapeutics' revenue in fiscal 2025?
Spero Therapeutics (SPRO) reported revenue of $66.8M for fiscal 2025.
What is Spero Therapeutics' annual revenue history?
Spero Therapeutics' annual revenue by fiscal year: 2020: $9.3M; 2021: $18.3M; 2022: $53.5M; 2023: $103.8M; 2024: $48.0M; 2025: $66.8M.
What was Spero Therapeutics' net income in fiscal 2025?
Spero Therapeutics reported net income of $8.6M for fiscal 2025.
What was Spero Therapeutics' earnings per share (EPS) in fiscal 2025?
Spero Therapeutics' diluted EPS was $0.15 for fiscal 2025 (adjusted for any later stock splits).
What was Spero Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Spero Therapeutics reported revenue of $0.
How much debt does Spero Therapeutics have?
Spero Therapeutics reported $91,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Spero Therapeutics are outstanding?
Spero Therapeutics reported a weighted average of 58.0 million basic shares outstanding in 2026 Q2.
What is Spero Therapeutics' market cap?
Based on its latest closing price, Spero Therapeutics (SPRO) has a market capitalization of about $66.7M.
When does Spero Therapeutics' fiscal year end?
Spero Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Spero Therapeutics headquartered?
Spero Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.